Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at ...

The stock of Hims & Hers Health Inc. (HIMS) fell more than 4% in after-hours trading after the telehealth company issued ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

The appointment coincides with Hims & Hers’ recent partnership with Novo Nordisk to offer the FDA-approved weight-loss drug Wegovy through its platform, enhancing access to obesity care. Following ...